Shares of Selecta Biosciences Inc (NASDAQ:SELB) have received a consensus recommendation of “Buy” from the six research firms that are covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $8.00.
SELB has been the topic of several recent analyst reports. Zacks Investment Research downgraded Selecta Biosciences from a “buy” rating to a “hold” rating in a report on Thursday, October 10th. Stifel Nicolaus reissued a “buy” rating and set a $6.00 price target on shares of Selecta Biosciences in a research note on Friday, November 8th. Finally, Needham & Company LLC restated a “buy” rating and set a $9.00 price objective on shares of Selecta Biosciences in a report on Friday, November 8th.
Selecta Biosciences stock traded down $0.08 during midday trading on Friday, reaching $1.57. The stock had a trading volume of 1,891 shares, compared to its average volume of 160,975. The firm has a market cap of $79.53 million, a price-to-earnings ratio of -0.54 and a beta of 1.17. Selecta Biosciences has a 52-week low of $1.28 and a 52-week high of $5.69. The company has a fifty day moving average of $1.49 and a 200 day moving average of $1.75.
Selecta Biosciences (NASDAQ:SELB) last announced its earnings results on Wednesday, November 13th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.28) by $0.02. On average, equities analysts forecast that Selecta Biosciences will post -1.23 EPS for the current fiscal year.
Several hedge funds and other institutional investors have recently bought and sold shares of SELB. Acadian Asset Management LLC bought a new position in shares of Selecta Biosciences in the second quarter worth about $31,000. Renaissance Technologies LLC lifted its holdings in Selecta Biosciences by 98.4% during the 2nd quarter. Renaissance Technologies LLC now owns 471,500 shares of the company’s stock valued at $844,000 after buying an additional 233,800 shares in the last quarter. A.R.T. Advisors LLC bought a new stake in Selecta Biosciences during the 2nd quarter valued at about $40,000. Vanguard Group Inc. lifted its holdings in Selecta Biosciences by 7.3% during the 2nd quarter. Vanguard Group Inc. now owns 1,620,305 shares of the company’s stock valued at $2,901,000 after buying an additional 109,806 shares in the last quarter. Finally, Paloma Partners Management Co purchased a new stake in Selecta Biosciences in the 2nd quarter valued at about $275,000. Hedge funds and other institutional investors own 39.55% of the company’s stock.
Selecta Biosciences Company Profile
Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes therapeutic enzymes, gene therapies, and other products and product candidates affected by undesired immune responses.
See Also: How much money do you need to begin day trading?
Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.